bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect bioAffinity Technologies to announce earnings of ($31.50) per share and revenue of $1.91 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 7:00 AM ET.
bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($5.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($31.50) by $25.61. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.91 million. bioAffinity Technologies had a negative net margin of 278.90% and a negative return on equity of 293.44%.
bioAffinity Technologies Stock Performance
Shares of NASDAQ:BIAF opened at $2.00 on Tuesday. The firm has a 50 day simple moving average of $5.10 and a 200 day simple moving average of $18.16. bioAffinity Technologies has a 52 week low of $1.96 and a 52 week high of $80.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.41 and a current ratio of 1.51.
Analyst Ratings Changes
Get Our Latest Report on bioAffinity Technologies
bioAffinity Technologies Company Profile
bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for lung disease, including lung cancer. Its work centers on applying flow cytometry and other technologies to analyze biological samples and support earlier disease detection. The company’s lead product, CyPath Lung, is a laboratory-developed test that analyzes sputum samples using proprietary technology. It is intended to help assess lung cancer risk in patients with suspicious pulmonary nodules and is offered through the company’s clinical laboratory subsidiary, Precision Pathology Services.
Featured Stories
- Five stocks we like better than bioAffinity Technologies
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
